| 1. |
|
|
| 2. |
- Wildner, E., et al.
(författare)
-
The Opportunity Offered by the ESSnuSB Project to Exploit the Larger Leptonic CP Violation Signal at the Second Oscillation Maximum and the Requirements of This Project on the ESS Accelerator Complex
- 2016
-
Ingår i: Advances in High Energy Physics. - : Hindawi Publishing Corporation. - 1687-7357 .- 1687-7365.
-
Tidskriftsartikel (refereegranskat)abstract
- The European Spallation Source (ESS), currently under construction in Lund, Sweden, is a research center that will provide, by 2023, the world's most powerful neutron source. The average power of the proton linac will be 5 MW. Pulsing this linac at higher frequency will make it possible to raise the average total beam power to 10 MW to produce, in parallel with the spallation neutron production, a very intense neutrino Super Beam of about 0.4 GeV mean neutrino energy. This will allow searching for leptonic CP violation at the second oscillation maximum where the sensitivity is about 3 times higher than at the first. The ESS neutrino Super Beam, ESSnuSB operated with a 2.0 GeV linac proton beam, together with a large undergroundWater Cherenkov detector located at 540 km from Lund, will make it possible to discover leptonic CP violation at 5 sigma. significance level in 56% (65% for an upgrade to 2.5 GeV beam energy) of the leptonic CP-violating phase range after 10 years of data taking, assuming a 5% systematic error in the neutrino flux and 10% in the neutrino cross section. The paper presents the outstanding physics reach possible for CP violation with ESSnuSB obtainable under these assumptions for the systematic errors. It also describes the upgrade of the ESS accelerator complex required for ESSnuSB.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Baussan, E., et al.
(författare)
-
A very intense neutrino super beam experiment for leptonic CP violation discovery based on the European spallation source linac
- 2014
-
Ingår i: Nuclear Physics B. - : Elsevier BV. - 0550-3213 .- 1873-1562. ; 885, s. 127-149
-
Tidskriftsartikel (refereegranskat)abstract
- Very intense neutrino beams and large neutrino detectors will be needed in order to enable the discovery of CP violation in the leptonic sector. We propose to use the proton linac of the European Spoliation Source currently under construction in Lund, Sweden, to deliver, in parallel with the spoliation neutron production, a very intense, cost effective and high performance neutrino beam. The baseline program for the European Spoliation Source linac is that it will be fully operational at 5 MW average power by 2022, producing 2 GeV 2.86 ms long proton pulses at a rate of 14 Hz. Our proposal is to upgrade the linac to 10 MW average power and 28 Hz, producing 14 pulses/s for neutron production and 14 pulses/s for neutrino production. Furthermore, because of the high current required in the pulsed neutrino horn, the length of the pulses used for neutrino production needs to be compressed to a few mu s with the aid of an accumulator ring. A long baseline experiment using this Super Beam and a megaton underground Water Cherenkov detector located in existing mines 300-600 km from Lund will make it possible to discover leptonic CP violation at 5 sigma significance level in up to 50% of the leptonic Dirac CP-violating phase range. This experiment could also determine the neutrino mass hierarchy at a significance level of more than 3 sigma if this issue will not already have been settled by other experiments by then. The mass hierarchy performance could be increased by combining the neutrino beam results with those obtained from atmospheric neutrinos detected by the same large volume detector. This detector will also be used to measure the proton lifetime, detect cosmological neutrinos and neutrinos from supernova explosions. Results on the sensitivity to leptonic CP violation and the neutrino mass hierarchy are presented.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Steinthorsdottir, V, et al.
(författare)
-
Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women
- 2020
-
Ingår i: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 11:1, s. 5976-
-
Tidskriftsartikel (refereegranskat)abstract
- Preeclampsia is a serious complication of pregnancy, affecting both maternal and fetal health. In genome-wide association meta-analysis of European and Central Asian mothers, we identify sequence variants that associate with preeclampsia in the maternal genome at ZNF831/20q13 and FTO/16q12. These are previously established variants for blood pressure (BP) and the FTO variant has also been associated with body mass index (BMI). Further analysis of BP variants establishes that variants at MECOM/3q26, FGF5/4q21 and SH2B3/12q24 also associate with preeclampsia through the maternal genome. We further show that a polygenic risk score for hypertension associates with preeclampsia. However, comparison with gestational hypertension indicates that additional factors modify the risk of preeclampsia.
|
|
| 11. |
- Stock, C., et al.
(författare)
-
Investigating episodic accretion in a very low-mass young stellar object
- 2020
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 643
-
Tidskriftsartikel (refereegranskat)abstract
- Very low-mass Class I protostars have been investigated very little thus far. Variability of these young stellar objects (YSOs) and whether or not they are capable of strong episodic accretion is also left relatively unstudied. Aims. We investigate accretion variability in IRS 54 (YLW52), a Class I very low-mass protostar with a mass of M∗ ∼ -0.2 M⊙. Methods. We obtained spectroscopic and photometric data with VLT/ISAAC and VLT/SINFONI in the near-infrared (J, H, and K bands) across four epochs (2005, 2010, 2013, and 2014). We used accretion-tracing lines (Paβ and Brγ) and outflow-tracing lines (H2 and [Fe II]) to examine physical properties and kinematics of the object. Results. A large increase in luminosity was found between the 2005 and 2013 epochs of more than 1 magnitude in the K band, followed in 2014 by a steep decrease. Consistently, the mass accretion rate (Macc) rose by an order of magnitude from ∼10-8 M⊙ yr-1 to ∼10-7 M⊙ yr-1 between the two early epochs. The visual extinction (AV) has also increased from ∼15 mag in 2005 to ∼24 mag in 2013. This rise in AV in tandem with the increase in Macc is explained by the lifting up of a large amount of dust from the disc of IRS 54, following the augmented accretion and ejection activity in the YSO, which intersects our line of sight due to the almost edge-on geometry of the disc. Because of the strength and timescales involved in this dramatic increase, this event is believed to have been an accretion burst possibly similar to bursts of EXor-type objects. IRS 54 is the lowest mass Class I source observed to have an accretion burst of this type, and therefore potentially one of the lowest mass EXor-type objects known so far.
|
|
| 12. |
- Wadelius, Mia, et al.
(författare)
-
The largest prospective warfarin-treated cohort supports genetic forecasting
- 2009
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 113:4, s. 784-792
-
Tidskriftsartikel (refereegranskat)abstract
- Genetic variants of cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) are known to influence warfarin dose, but the effect of other genes has not been fully elucidated. We genotyped 183 polymorphisms in 29 candidate genes in 1496 Swedish patients starting warfarin treatment, and tested for association with response. CYP2C9*2 and *3 explained 12% (P = 6.63 x 10(-34)) of the variation in warfarin dose, while a single VKORC1 SNP explained 30% (P = 9.82 x 10(-100)). No SNP outside the CYP2C gene cluster and VKORC1 regions was significantly associated with dose after correction for multiple testing. During initiation of therapy, homozygosity for CYP2C9 and VKORC1 variant alleles increased the risk of over-anticoagulation, hazard ratios 21.84 (95% CI 9.46; 50.42) and 4.56 (95% CI 2.85; 7.30), respectively. One of 8 patients with CYP2C9*3/*3 (12.5%) experienced severe bleeding during the first month compared with 0.27% of other patients (P = .066). A multiple regression model using the predictors CYP2C9, VKORC1, age, sex, and druginteractions explained 59% of the variance in warfarin dose, and 53% in an independent sample of 181 Swedish individuals. In conclusion, CYP2C9 and VKORC1 significantly influenced warfarin dose and predicted individuals predisposed to unstable anticoagulation. Our results strongly support that initiation of warfarin guided by pharmacogenetics would improve clinical outcome.
|
|
| 13. |
|
|
